HUE027911T2 - Új antitestek - Google Patents

Új antitestek Download PDF

Info

Publication number
HUE027911T2
HUE027911T2 HUE08834260A HUE08834260A HUE027911T2 HU E027911 T2 HUE027911 T2 HU E027911T2 HU E08834260 A HUE08834260 A HU E08834260A HU E08834260 A HUE08834260 A HU E08834260A HU E027911 T2 HUE027911 T2 HU E027911T2
Authority
HU
Hungary
Prior art keywords
antibody
vegf
antibodies
disease
sequence
Prior art date
Application number
HUE08834260A
Other languages
English (en)
Inventor
Wei-Ching Liang
Gregory D Plowman
Yan Wu
Weilan Ye
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HUE027911T2 publication Critical patent/HUE027911T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (8)

  1. m ANTITESTEK Szabadalmi igénypontok % Humanizálj α5β1 integrin elleni antitest, amely tartalmaz olyan könnyűlánc variábilis dómén szekvenciát, amely tartalmaz (1) olyan LHVR1~et, amely tartalmazza a KASOSWGSöYA aminosav-szekvenciát (2) olyan LHVR24, amely iart&amp;teazza az STSYRYS amioösav-szekvenoiát, és (3) olyan LHVR3-at, amely tartalmazza a ÉtTYiSYRFT aminosav-szekvenciát; valamint olyan nehézlárto variábilis dómén szekvenciát, amely tartalmaz (1) olyan HHVR1 eí, amely tartalmazza a GYTFTDYYLY vagy a GYÏFSDYYLY aminosav-szekvenciát, (2) olyan HHVR2~t, amely tartalmazza a G1SRSSGGTTF&amp;DAF1EG amlrtosavmzekvenclát, és (3) olyan HHVR3~ai amely tartalmazza a DAYGOÄYFPV amínosav-szekveooiát. 2< öoßl integrin elleni antitest, amely tartalmaz olyan könnyű lánc variábilis domént, amelynek a szekvenciája a SEQ ID NO:2 szerinti, és olyan nehézlánc variábilis domént, amelynek a szekvenciája a SEQ 10 NG:6 szerinti.
  2. 3, Az 1. igénypont szerinti antitest, ahol a könnyűlánc variábilis donién szekvenciája a SEQ 1D NO:3 szerinti, és a nebéziánc variábilis donién szekvenciája a SEQ ID MÖ:8 szerinti.
  3. 4, Az 1, 2. vagy 3. igénypont szerinti antitest, illői az antitest nem köti az aitiVbêtaâ Integrin! vagy nem köti az aiíaVöétaS integrin! vagy nem köti az alfaVbétal integrint. &amp; Az előző Igénypontok bármelyike szerinti antitest aboi az antitest tartalmazza egy humán IgG egy Fc szekvenciáját, ahol a búmén IgG adott esetben hlgGI vagy hlgG4. € Az 5. igénypont szerinti antitest, ahol az antitest tartalmaz olyan Fészek venciát; amelybét hiányzik az aniitestíuggő celíuJáris cítoíoxicitási (ADCG) effektorfunkció, ahol az Fc-szekvencia adott esetben tartalmaz egy D205A szubsztitúciót. Az 1-4. Igénypontok bármelyiké szerinti antitest, amely antitest a következők (scFv), Fv-fragmens; diatest és lineáris antitest. S, Az 1-6. igénypontok bármelyike szerinti antitest, ahol az antitest muitíspeciííkus antitest. 3< Az 1-5. igénypontok bármelyike szerinti antitest, amely terápiás ágenshez van konjugálva, ahol a terápiás ágens adott esetben a következők által alkotott csoportból kerül kiválasztásra: citotoxlkus ágens, radiolzotóp és kemoterápiás ágens,
  4. 10, Az 1-6. igénypontok bármelyike szerinti antitest, amely jelöléshez van konjugálva, ahol a jelölés adott esetben a következők által alkotott csoportból kerül kiválasztásra: radiolzotóp, fluoreszcens festék és enzim.
  5. 11, Készítmény, amely tartalmazza az előző igénypontok bármelyike szerinti antitestet, valamint tartalmaz gyégyászaiiai elfogadható hordozót.
  6. 12, Az 1-9, igénypontok bármelyike szerinti, α5β1 infegrin elleni antitest egy alany betegségének vagy rendellenességének kezelésére szolgáló eljárásban történő alkalmazásra, ahol a betegség vagy rendellenesség rendellenes angfogenezisseí jár, ahol az o5ß1 infegrin elleni antitestet VEGF-antagonistávai kombináltan adjuk be vagy ahoi az alanyt a VEGF-antagonistával kezeljük, majd ezt kővetően beadjuk neki az αδβ1 integrln elleni antitestet, ahol a betegség adott esetben rák, szembetegség vagy autoimmun betegség, és ahol a VEGF-antagonista a következik által alkotott csoportból kerül kiválasztásra: antitest, immunadhezin, peptíiest és olyan oukleinsav, amely sztringens körülmények között hibridlzál egy VEGF~et kódoló nukleinsav-moíekulával.
  7. 13, Az anti--oSß1 antitest alkalmazásra a 12, igénypont szerinti, ahol a VEGF--antagonists kötődése a humán VEGF-hez kompetitiven gátolható bevacizumabbaí, ahol a VÉGF-antagonista adott esetben bevaclzumab
  8. 14, Készítmény, amely tartalmaz VEGF-antagonistát, az 1-9. igénypontok bármelyike szerinti antitestet és gyógyászatilag elfogadható hordozót, ahol a VEGF-antagonlsta a következek által alkotott csoportból kerül kiválasztásra: egy antitest, egy Immunadhezln, egy peptitest és olyan nukleiesav, amely sztringens körülmények között hibridizál egy VEGF-et kódoló oukleinsav-molekulával, 15, A 14, igénypont szerinti készítmény egy alany egy betegségének vagy egy rendellenességének kezelésére szolgáló eljárásban történő alkalmazásra, ahol a betegség vagy rendellenesség rendellenes anglogenezissel jár, ahol a betegség adott esetben rák, szembetegség vagy autoimmun betegség.
HUE08834260A 2007-09-26 2008-09-25 Új antitestek HUE027911T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97547107P 2007-09-26 2007-09-26

Publications (1)

Publication Number Publication Date
HUE027911T2 true HUE027911T2 (hu) 2016-11-28

Family

ID=40329277

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08834260A HUE027911T2 (hu) 2007-09-26 2008-09-25 Új antitestek

Country Status (22)

Country Link
US (3) US7973138B2 (hu)
EP (1) EP2200700B1 (hu)
JP (1) JP2011501656A (hu)
KR (1) KR20100065162A (hu)
CN (1) CN101888878B (hu)
AR (1) AR066170A1 (hu)
AU (1) AU2008304452B2 (hu)
BR (1) BRPI0816049A2 (hu)
CA (1) CA2698609A1 (hu)
CL (1) CL2008002856A1 (hu)
CO (1) CO6260094A2 (hu)
DK (1) DK2200700T3 (hu)
HR (1) HRP20160308T1 (hu)
HU (1) HUE027911T2 (hu)
MX (1) MX2010003325A (hu)
MY (1) MY151191A (hu)
NZ (1) NZ584838A (hu)
PE (1) PE20091029A1 (hu)
RU (1) RU2490277C2 (hu)
SI (1) SI2200700T1 (hu)
TW (1) TWI547503B (hu)
WO (1) WO2009042746A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010003325A (es) 2007-09-26 2010-04-09 Genentech Inc Anticuepos novedosos.
PE20120770A1 (es) 2009-03-25 2012-07-10 Genentech Inc ANTICUERPOS ANTI alfa5ß1 CON ACTIVIDAD SOBRE GLIOBLASTOMAS
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
CA2760246A1 (en) 2009-05-08 2010-11-11 Weilan Ye Humanized anti-egfl7 antibodies and methods using same
US8956600B2 (en) 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US20130058926A1 (en) * 2011-08-30 2013-03-07 Shiseido Company, Ltd. Method for alleviating and/or preventing skin reddening
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
WO2013152011A1 (en) * 2012-04-02 2013-10-10 Ab Biosciences, Inc. Novel human control antibodies and uses therefor
EP2847231B1 (en) 2012-05-10 2019-07-10 Bioatla LLC Multi-specific monoclonal antibodies
JP6324970B2 (ja) 2012-09-27 2018-05-23 バイオケア メディカル， エルエルシー 抗ウロプラキンｉｉ抗体システムおよび方法
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
WO2014105910A1 (en) 2012-12-26 2014-07-03 Oncosynergy, Inc. ANTI- INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
CA2898239A1 (en) 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
WO2014122143A1 (en) * 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
ES2720483T3 (es) 2013-02-28 2019-07-22 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti p40
WO2015051320A2 (en) 2013-10-03 2015-04-09 Biocare Medical, Llc Anti-sox10 antibody systems and methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
CN108693004B (zh) * 2018-05-24 2020-08-04 中国农业科学院农业质量标准与检测技术研究所 一种检测菜籽粕中是否掺杂抗生素滤渣的方法
US11384146B2 (en) * 2019-04-01 2022-07-12 Curia Ip Holdings, Llc BTLA-binding antibodies for modulating immune response and treating disease
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
CN114688461A (zh) * 2020-12-31 2022-07-01 青岛海尔施特劳斯水设备有限公司 一种漏水检测方法及***
CN113133431A (zh) * 2021-02-25 2021-07-20 中南大学 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用
CN114073996B (zh) * 2021-11-24 2023-04-14 中山大学 一种嵌套式微井阵列芯片及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540933A (en) 1985-05-31 1996-07-30 La Jolla Cancer Research Foundation Isolation and use of fibronectin receptor
EP0330506A3 (en) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
US20020146410A1 (en) 1992-05-22 2002-10-10 Helmut Eckert Monoclonal antibodies and their use
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5627263A (en) 1993-11-24 1997-05-06 La Jolla Cancer Research Foundation Integrin-binding peptides
ATE244306T1 (de) 1994-12-20 2003-07-15 Merck Patent Gmbh Monoklonaler antikörper gegen das alpha-v- integrin
KR20010034327A (ko) 1998-01-23 2001-04-25 플레믹 크리스티안 모노클로날 항체 항 αν-인테그린, 및 피브로넥틴에 대한ανβ6-인테그린 부착을 억제하기 위한 그의 용도
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
WO1999058139A2 (en) 1998-05-08 1999-11-18 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9909392D0 (en) 1999-04-24 1999-06-23 Imp Cancer Res Tech Treatment, imaging and diagnosis of disease
US20020019330A1 (en) 1999-08-11 2002-02-14 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20040009494A1 (en) 1999-08-11 2004-01-15 Richard Murray Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators
EP1204764A2 (en) 1999-08-11 2002-05-15 EOS Biotechnology, Inc. Methods of screening for angiogenesis modulators
US20020015970A1 (en) 1999-08-11 2002-02-07 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20030152926A1 (en) 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20040259152A1 (en) 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
JP2004531249A (ja) 2001-02-14 2004-10-14 プロテイン デザイン ラブス インコーポレイティド 血管新生の診断方法、組成物、及び血管新生モジュレータのスクリーニング方法
WO2002086443A2 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2002098358A2 (en) 2001-06-04 2002-12-12 Eos Biotechnology, Inc. Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
EP1517998A2 (en) 2001-06-18 2005-03-30 EOS Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20040033495A1 (en) 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20070042360A1 (en) 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP1434881A4 (en) 2001-09-17 2005-10-26 Protein Design Labs Inc METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20060241067A1 (en) 2002-06-25 2006-10-26 Varner Judith A Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
AU2003299529A1 (en) 2002-07-16 2004-06-03 University Of Medicine And Dentistry Of New Jersey Alpha 5 beta 1 and its ability to regulate the cell survival pathway
CN100369930C (zh) * 2002-11-26 2008-02-20 Pdl生物制药股份有限公司 调节血管生成的α5β1整合素的嵌合的和人源化的抗体
WO2004048938A2 (en) 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
CA2520121A1 (en) 2003-04-03 2004-10-21 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
CA2560508A1 (en) 2004-03-24 2005-10-06 Pdl Biopharma, Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
PT1819359E (pt) 2004-12-09 2015-05-28 Janssen Biotech Inc Imunoconjugados anti-integrina, métodos para a sua produção e sua utilização
CN101360736A (zh) 2005-11-23 2009-02-04 阿斯利康(瑞典)有限公司 L-丙氨酸衍生物
JP2009516729A (ja) 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ Ｌ−フェニルアラニン誘導体
CN101379028A (zh) 2006-02-09 2009-03-04 阿斯利康(瑞典)有限公司 化学化合物
BRPI0709338A2 (pt) * 2006-03-21 2011-07-12 Genentech Inc anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf
KR20090027218A (ko) 2006-05-24 2009-03-16 바이엘 쉐링 파마 악티엔게젤샤프트 면역원성이 감소된, 고친화도 인간 및 인간화된 항-α5β1 인테그린 작용 블로킹 항체
MX2010003325A (es) 2007-09-26 2010-04-09 Genentech Inc Anticuepos novedosos.
BRPI0906387A2 (pt) 2008-02-05 2015-07-07 Bristol Myers Squibb Co Anticorpos alfa 5 - beta 1 e seus usos

Also Published As

Publication number Publication date
NZ584838A (en) 2012-08-31
CO6260094A2 (es) 2011-03-22
CL2008002856A1 (es) 2009-01-16
US7973138B2 (en) 2011-07-05
TW200924794A (en) 2009-06-16
MX2010003325A (es) 2010-04-09
WO2009042746A1 (en) 2009-04-02
US20120148572A1 (en) 2012-06-14
RU2490277C2 (ru) 2013-08-20
CA2698609A1 (en) 2009-04-02
US20090098112A1 (en) 2009-04-16
DK2200700T3 (en) 2016-04-11
HRP20160308T1 (hr) 2016-04-22
PE20091029A1 (es) 2009-08-19
EP2200700A1 (en) 2010-06-30
MY151191A (en) 2014-04-30
CN101888878B (zh) 2014-05-21
JP2011501656A (ja) 2011-01-13
CN101888878A (zh) 2010-11-17
SI2200700T1 (sl) 2016-04-29
AU2008304452B2 (en) 2014-01-16
US20120156129A1 (en) 2012-06-21
TWI547503B (zh) 2016-09-01
EP2200700B1 (en) 2016-01-13
US8840887B2 (en) 2014-09-23
BRPI0816049A2 (pt) 2019-09-24
US9284376B2 (en) 2016-03-15
AU2008304452A1 (en) 2009-04-02
KR20100065162A (ko) 2010-06-15
RU2010116184A (ru) 2011-11-10
AR066170A1 (es) 2009-07-29

Similar Documents

Publication Publication Date Title
DK2200700T3 (en) Novel antibodies
AU2007319757B2 (en) Combinatorial therapy involving alpha5beta1 antagonists
AU2010229479B2 (en) Novel anti-alpha5beta1 antibodies and uses thereof